TL;DR
This work establishes the KMT5C-HDAC1 axis as a central epigenetic switch that governs HCC stemness and progression, revealing a co-targeting strategy for the treatment of aggressive HCC.
COL4A4 acts as a methylation-silenced RCC tumor suppressor that negatively modulates JAK2/STAT3 signaling and correlates with TME features, representing a potential epigenetic therapeutic target.
This work identifies RNA‐binding motif protein 25 (RBM25) as a potent oncogenic driver that is overexpressed in HCC and correlates with dismal patient prognosis and nominate RBM25 as a viable prognostic biomarker and therapeutic target.
It is indicated that MPT0G521 disrupts the G2/M activation and mitotic machinery, thereby suppressing proliferative and resistant GBM subpopulations and holding strong promise for overcoming GBM heterogeneity and reducing recurrence.
Findings indicate that the c-Myc-CASC19/HDAC1-NPM1 axis acts as a potential prognostic biomarker candidate for GC and may represent a therapeutic vulnerability worthy of future investigation.
ZBTB10 is identified as a suppressor of ccRCC progression that transcriptionally represses GPX4, a central inhibitor of ferroptosis and an epigenetic mechanism linking ZBTB10 to ferroptosis in ccRCC is revealed and targeting the ZBTB10/DNMT1/FBXW4/GPX4 axis may provide a therapeutic strategy for limiting ccRCC progress...
The findings establish the ZEB1–IL-6 axis as an important regulator of triple-negative breast cancer (TNBC) stemness and indicate that ZEB1-dependent IL-6 activation is influenced by the local epigenetic context, which supports further investigation of the ZEB1-high TNBC.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
